HomeCompareSIXS vs MRK

SIXS vs MRK: Dividend Comparison 2026

SIXS yields 1.89% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $8.3K in total portfolio value
10 years
SIXS
SIXS
● Live price
1.89%
Share price
$51.99
Annual div
$0.98
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$214.12
Full SIXS calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SIXS vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSIXSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SIXS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SIXS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SIXS
Annual income on $10K today (after 15% tax)
$161.01/yr
After 10yr DRIP, annual income (after tax)
$182.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $625.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SIXS + MRK for your $10,000?

SIXS: 50%MRK: 50%
100% MRK50/50100% SIXS
Portfolio after 10yr
$26.6K
Annual income
$582.21/yr
Blended yield
2.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SIXS
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SIXS buys
0
MRK buys
0
No recent congressional trades found for SIXS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSIXSMRK
Forward yield1.89%3.25%
Annual dividend / share$0.98$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$22.4K$30.7K
Annual income after 10y$214.12$950.29
Total dividends collected$2.0K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SIXS vs MRK ($10,000, DRIP)

YearSIXS PortfolioSIXS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,889$189.42$11,192$351.54$303.00MRK
2$11,844$192.78$12,524$392.70$680.00MRK
3$12,870$195.97$14,015$438.65$1.1KMRK
4$13,969$199.00$15,682$489.96$1.7KMRK
5$15,149$201.87$17,547$547.23$2.4KMRK
6$16,414$204.60$19,632$611.16$3.2KMRK
7$17,770$207.18$21,963$682.53$4.2KMRK
8$19,224$209.63$24,571$762.18$5.3KMRK
9$20,782$211.94$27,486$851.08$6.7KMRK
10$22,450$214.12$30,745$950.29$8.3KMRK

SIXS vs MRK: Complete Analysis 2026

SIXSStock

Under normal circumstances, the fund invests at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in small-capitalization equity securities. The Sub-Adviser considers small-capitalization companies to be those with market capitalizations within the range of the market capitalization of companies included in the S&P SmallCap 600 Index. Although it invests primarily in small-capitalization securities, the fund may invest in equity securities of companies of any capitalization. The equity securities in which it invests are mainly common stocks.

Full SIXS Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SIXS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SIXS vs SCHDSIXS vs JEPISIXS vs OSIXS vs KOSIXS vs MAINSIXS vs JNJSIXS vs ABBVSIXS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.